Simon Morin (Talk | contribs) |
Simon Morin (Talk | contribs) |
||
Line 191: | Line 191: | ||
<embed src="https://static.igem.org/mediawiki/2017/a/a7/UPMC_team_2017_Entrepreunership_swot.pdf" width="100%" style="margin-left:auto;margin-right:auto;" height="1000" type='application/pdf'> | <embed src="https://static.igem.org/mediawiki/2017/a/a7/UPMC_team_2017_Entrepreunership_swot.pdf" width="100%" style="margin-left:auto;margin-right:auto;" height="1000" type='application/pdf'> | ||
− | + | <br> | |
+ | <h2 class="content-title">Buisness Plan</h2> | ||
+ | |||
<br> <br> | <br> <br> | ||
<img class="img-responsive" src="https://static.igem.org/mediawiki/2017/9/9a/UPMC_team_2017_buisness_plan.jpg" alt=""> | <img class="img-responsive" src="https://static.igem.org/mediawiki/2017/9/9a/UPMC_team_2017_buisness_plan.jpg" alt=""> |
Revision as of 03:40, 16 December 2017
Entrepreneurship
Days after days, the recombinant proteins production is growing as a vital industrial science, in major fields of work such as healthcare or agronomy. Optimization of this production, that to says reducing the cost and time of production of these molecules, is the main priorty of companies of this sector. Another major challenge remain to further automatize these processes.
When we started the project our main goal was to find a solution that could help to resolve the issues of the lack of access to proper healthcare in developing contries. To do so, we investigated the causes of the healthcare failures in different regions of the world that leads to a lower life span compared to developed countries. Beyond a lack of basal hygienic prevention in an environment often favourable to the growth of various pathogenic agents, the lack of access to healthcare appeared as an obvious source of this lower quality of health.
Through our box, we focused more specifically on the lack of access to preventive and curative protein drugs. We want to innovate in the way we produce already existing therapeutic molecules.
We then focused on 3 main causes of the lack of access to drugs in the world :
1) The lack of financial means for the purchase and setting up of drug production
2) Geographical isolation of the countries concerned
3) Storage and transport of drugs issues
Strategic Business Unit (SBU)
In order to have a more general view of the drug market, we have set up a SBU table around the question of the lack of access to healthcare.
Large companies do not provide sufficient answers to the 3 main reasons of the lack of access to care in developing countries. This explains the specific lack of drugs in these countries even though
The BioMaker Factory Lack of access to healthcare
Alternative Solutions
Companies from
developed or in
developing countries
Client expectations profile
Companies TBMF Geographical accessibility + /- ++ Affordability + /- ++ Significant amount /storage + /- - Emergency / Quick obtaining + - Multiple drugs through a same tool + ++ Safe ++ ++ Userfriendly + ++ (automation ) Efficiency Risk-Benefit balance ++ ++
Users Geographically isolated countries and / or having financial problems Hospitals / clinics Local dispensaries NGO Any access to care system
there are existing treatments. In addition, this table allows us to highlight the customers expectations and place the contribution of our box according to them.
Our major difference from large companies lies in the ability to get instantaneously :
- A significant amount of therapeutic molecules
- Wich palliate the medical emergency.
Moreover, for a simplified heterologous synthesis we limited our box to the production of protein drugs for now, which is already a sufficient challenge. Although they are criteria of the client expectations profile there is a notable market around drugs needed in a quantity and in a short time lapse which correspond to one cycle production of our box. This specifity of our project will be a key asset for our future business development. Moreover, the local production through our box bypasses the storage and transport of drugs issues that can often occur, and allow a controlled and reliable production
of the drugs which is a main issue, in sub-Saharan Africa for example.
We can therefore place our box on the market of protein drugs with a punctual need that can wait for a 8-10 hours production and that are needed in micrograms to milligrams per dose. This drugs dosage would enable the treatment of multiple people with one production cycle of our box. In this market, we can answer the 3 main causes of the lack of access to healthcare mentioned before. We are therefore innovating on the production process of already existing protein drugs. Thus, our strategic segment is the developing countries.
Drug candidates
We then researched therapeutic proteins which are nowadays needed, and matching with the specific reasons regarding the lack of access to healthcare we explained before and that our box can constitue a solution for. The pathology treated by these drug candidates has to:
- Allow a minimum action time of about 8h to 10 hours
- Be curable by a quantity of active substances from micrograms to milligrams
We then selected the 3 types of diseases, we presented in the state of art of the current medical needs worldwide.